RayzeBio is a technology company.
RayzeBio has raised $425.0M across 4 funding rounds.
Key people at RayzeBio.
RayzeBio has raised $425.0M in total across 4 funding rounds.
Key people at RayzeBio.
RayzeBio has raised $425.0M in total across 4 funding rounds.
RayzeBio's investors include Cambridge Innovation Capital, Forbion, Sofinnova Investments, Atlas Venture, KohFounders, RA Capital, Samsara BioCapital, venBio, Versant Ventures, Longwood Fund, Venrock.
RayzeBio is a biotechnology company developing precision radiopharmaceutical therapies (RPTs) using actinium-225 (Ac-225), an alpha-emitting isotope, to target and kill cancer cells in solid tumors.[1][2][3] Its lead product, RYZ101, is in Phase 3 trials for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), addressing unmet needs for patients progressing beyond standard care, with a pipeline extending to small cell lung cancer, hepatocellular carcinoma, and others.[2][6] Now a Bristol Myers Squibb (BMS) company, RayzeBio operates a state-of-the-art manufacturing hub in Indianapolis for rapid, on-demand production and global delivery of clinical doses.[2][6]
The company serves oncology patients and physicians by enabling theranostic approaches—using the same drug conjugate for tumor imaging and targeted therapy—improving patient selection and outcomes through high-potency, localized radiation that minimizes damage to healthy tissue.[1][2][3]
RayzeBio was established in 2020 as a biotechnology company focused on tumor-targeted radiopharmaceuticals, launching with a $45 million Series A financing led by investors like venBio Partners.[3][4] Key leadership includes CEO Ken Song, M.D., who emphasized the company's entrepreneurial drive, and President Ben Hickey, involved in recent expansions.[2][4] The idea emerged from coordinating target selection (clinically validated solid tumor targets), binder selection (novel macrocyclic peptide mimetics via partnerships like PeptiDream), and isotope selection (Ac-225 for its potent, focused cell-killing).[3][4]
Early traction included a 2021 strategic collaboration with Nimble Therapeutics to discover peptide-based RPTs, expanding the pipeline with upfront payments, milestones, and royalties.[4] A pivotal moment came with its acquisition by Bristol Myers Squibb, integrating RayzeBio's innovation into BMS's oncology platform and enabling the 2024 opening of a dedicated manufacturing facility.[2][6]
RayzeBio rides the radiopharmaceutical therapy wave, a next-generation oncology trend shifting from broad chemotherapy to precision radiation delivery directly to tumors.[1][2] Timing aligns with surging demand for targeted therapies in hard-to-treat cancers like GEP-NETs (200,000 U.S. patients), where standard options fail, fueled by advances in isotope supply and peptide discovery platforms.[2][3][4]
Market forces favor it: growing clinical validation of RPTs as diagnostics and therapeutics, regulatory momentum (e.g., Phase 3 for RYZ101), and BMS's resources amplifying scale.[2][6] RayzeBio influences the ecosystem by pioneering Ac-225 applications, partnering for binder tech, and building infrastructure that accelerates RPT adoption, potentially redefining solid tumor treatment paradigms.[1][4]
RayzeBio's Phase 3 readout for RYZ101 in GEP-NETs could validate Ac-225 RPTs, unlocking commercialization and pipeline expansion into lung, liver, and beyond.[2] Trends like AI-driven discovery, supply chain maturation for alpha-emitters, and theranostics integration will propel growth, with the Indianapolis hub enabling rapid iteration.[2][4]
As a BMS entity, its influence will evolve from innovator to platform leader, potentially delivering first-in-class therapies that transform survival rates and inspire broader RPT investment—positioning it at the forefront of precision oncology's transformation of lives.[1][6]
RayzeBio has raised $425.0M across 4 funding rounds. Most recently, it raised $160.0M Series D in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $160.0M Series D | Cambridge Innovation Capital, Forbion, Sofinnova Investments | |
| Jun 1, 2021 | $110.0M Series C | Atlas Venture, KohFounders, RA Capital, Samsara BioCapital, venBio, Versant Ventures | |
| Dec 1, 2020 | $110.0M Series B | Atlas Venture, Longwood Fund, RA Capital, Samsara BioCapital, venBio, Venrock, Versant Ventures | |
| Oct 1, 2020 | $45.0M Series A | Atlas Venture, RA Capital, Samsara BioCapital, venBio, Versant Ventures |
